Mechanisms by which chemotherapeutic agents augment the antitumor effects of tumor necrosis factor: Involvement of the pattern shift of cytokines from Th2 to Th1 in tumor lesions

Anticancer Research

Volumn 18, Issue 5 D, 1998, Pages 3957-3964

  Inagawa, Hiroyuki ^a   Nishizawa, Takashi ^a   Honda, Teruko ^a   Nakamoto, Takeru ^a   Takagi, Koichi ^a   Soma, Gen Ichiro ^a,b  

^a TAKANO HOSPITAL   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antitumor therapy; Cyclophosphamide; Innate immunity; LPSp; ONO 4007; TGF

Indexed keywords

2 DEOXY 3 O (9 PHENYLNONANOYL) 2 [3 (9 PHENYLNONANOYLOXY)TETRADECANOYLAMINO]GLUCOPYRANOSE 4 SULFATE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTOKINE; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MESSENGER RNA; SODIUM 2 DEOXY 2 [(9 PHENYLNONANOYLOXY)TETRADECANOYL]AMINO 3 O (9 PHENYLNONANOYL) DEXTRO GLUCOPYRANOSE 4 SULFATE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER REGRESSION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG MECHANISM; FIBROSARCOMA; HELPER CELL; IMMUNE STATUS; INTRADERMAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; CYTOKINES; LIPID A; LIPOPOLYSACCHARIDES; LIVER NEOPLASMS, EXPERIMENTAL; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED STRAINS; MOLECULAR WEIGHT; NEOPLASMS, EXPERIMENTAL; TH1 CELLS; TH2 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031773870     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (34)

1. Asher A, Mule JJ, Reichert CM, et al: Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumor in vivo. J Immunol 138: 963-974, 1987.
2. Blick M, Shervin SA, Rosenblum M, et al: Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 47: 2968-2989, 1987.
3. Feinberg B, Kurzrock R, Talpa ZM. et al: A phase I trial of intravenously administered recombinant tumor necrosis factor in patients with advanced cancer. J Clin Oncol 6: 1328-1334, 1988.
4. McIntosh JK, Mule JJ, Merino MJ, et al: Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-a. Cancer Res 48: 4011-4017, 1988.
5. Soma G-I, Tsuji Y, Tanabe Y, et al: Biological activities of novel recombinant tumor necrosis factor having N-terminal amino acid sequences derived from cytotoxic factors by THP-1 cells. J Biol Resp Modif 7: 587-595, 1988.
6. Ten Hagen TLM, Eggermont AMM: A rat extremity soft tissue sarcoma model for the study of systemic treatment with Stealth liposome-encapsulated tumor necrosis factor-a and cytotoxic agents. Advanced Drug Deliv Rev 24: 245-256, 1997.
7. Eggermont AMM, Koops HM, Klausner JM, et al: Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. Annals Surgery 224: 756-765, 1997.
8. Manusama ER, Nooijen PTGA, Stavast J, et al: Synergistic antitumor effect of recombinant human tumour necrosis factor a with melphalan in isolated limb perfusion in the rat. Br J Surgery 83: 551-555, 1996.
9. Lejeune FJ: High dose recombinant tumor necrosis factor (rTNFα) administered by isolation perfusion of advanced tumors of the limbs: a model for biochemotherapy of cancer. Eur J Cancer 31A: 1009-1016, 1995.
10. Inagawa H, Nishizawa T, Noguchi K, et al: Anti-tumor effect of lipopolysaccharide by intradermal administration as a novel drug delivery system. Anticancer Res 17: 2153-2158, 1997.
11. Inagawa H, Oshima H, Soma GI, Mizuno D: TNF induces endogenous TNF in vivo: The basis of EET therapy as a combination of rTNF together with endogenous TNF. J Biol Resp Modif 7: 596-607, 1988.
12. Soma GI Mizuno D: Exogenous and endogenous tumour necrosis factor therapy. Cancer Surveys 8: 837-852, 1989.
13. Tomita M, Fuchino Y, Otsuka K, Shinohara T, Tanaka S-N, Umeno T, Ikeda S: Clinical effects of exogenous / endogenous TNF therapy on metastatic lesions of 34 colorectal cancer patients. Anticancer Res 18: 3937-3940, 1998.
14. Yamazaki K, Hasegawa S, Futami K, Arima S: Endogenous TNF induction therapy using rTNF-SaM2 in patients with pulmonary metastases from colorectal cancer. Anticancer Res 18: 3931-3936, 1998.
15. Weiskirch LM, Bar-Dagan Y, Mokyr MB: Transforming growth factor-β-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy. Cancer Immunol Immunother 38: 215-224, 1994.
16. Gorelik L, Rubin M, Prokhorova A, Mokyr MB: Importance of TNF production for the curative effectiveness of low dose melphalan therapy for mice bearing a large MOPC-315 tumor. J Immunol 154: 3941-3951, 1995.
17. Gorelik L, Mokyr MB: Low-dose-melphalan-induced up-regulation of type-1 cytokine expression in the s.c. tumor nodule of MOPC-315 tumor bearers and the role of interferon γ in the therapeutic outcome. Cancer Immunol Immunother 41: 363-374, 1995.
18. Nishizawa T, Inagawa H, Oshima H, et al: Homeostasis as regulated by activated macrophage. I. Lipopolysaccharide from wheat flour: Isolation, purification and some biological activities. Chem Pharm Bull 40: 479-483, 1992.
19. Matsumoto N, Abe Y, Akimoto A, et al: Restoration of immune responses in tumor-bearing mice by ONO-4007, an antitumor lipid A derivative. Immunopharmacol 36: 69-78, 1997.
20. Hattori Y, Szabo C, Gross S, et al: Lipid A and lipid A analogue antitumor compound ONO-4007 induce nitric oxide sythetase in vitro and in vivo. Eur J Parmacol 297: 83-90, 1995.
21. Tsukioka D, Nishizawa T, Miyase T, et al: Structural characterization of lipid A obtained from Pantoea agglomerans lipopolysaccharide. FEMS Microbiol Let 149: 239-244, 1997.
22. Nishizawa T, Okutomi T, Inagawa H, et al: Intratumoural tumour necrosis factor induction in tumour bearing mice by exogenous/ endogenous tumour necrosis factor therapy as compared with systemic administration of various biological response modifiers. Mol Biother 3: 224-230, 1991.
23. Satoh M, Inagawa H, Shimada Y, et al: Endogenous production of tumor necrosis factor in normal mice and human cancer patients by interferons and other cytokines combined with biological response modifiers of bacterial origin. J Biol Resp Modif 6: 512-524, 1987.
24. Oshiro S, Inagawa H, Soma G-I, Mizuno D: Antitumor effect of exogenous/endogenous TNF (EET) therapy with cyclophosphamide on C6 glioma in rat. Cancer Biother 9: 359-367, 1994.
25. Ehrke MJ, Verstovsek S, Krawczyk CM, et al: Cyclophosphamide plus tumor necrosis factor-α chemo-immunotherapy cured mice: life-long immunity and rejection of re-implanted primary lymphoma. Int J Cancer 63: 463-471, 1995.
26. Inagawa H, Ohshiro S, Nishizawa T, et al: Augmentation of antitumor effect of endogenously induced tumor necrosis factor by cyclophosphamide. Anticancer Res 17: 55-60, 1997.
27. Gérain J, Liénard D, Ewalenko P, Lejeune FJ: High serum levels of TNF-α after its administration for isolation perfusion of the limb. Cytokine 4: 585-591, 1992.
28. Kuppen PJK, Jonges LE, van de Velde CJH et al: Liver and tumour tissue concentrations of TNF-α in cancer patients treated with TNF-α and melphalan by isolated liver perfusion. Br J Cancer 75: 1497-1500, 1997.
29. Marlor CW, Webb DL, Bombara MP, et al: Expression of vascular cell adhesion molecule-1 in fibroblast like synoviocytes after stimulation with tumour necrosis factor. Am J Pathol 140: 1055-1060, 1992.
30. Palladino MAJr, Shalby MR, Kramer SM, et al: Characterization of the anti-tumour activities of human tumour necrosis factor-alpha and the comparison with other cytokines: induction of tumour-specific immunity. J Immunol 138: 4023-4032, 1987.
31. Renard N, Liénard D, Lespagnrd L, et al: Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNFα). Int J Cancer 57: 656-663, 1994.
32. Oh JW, Katz A, Harroch S, et al: Unmasking by soluble IL-6 receptor of IL-6 effect on metastatic melanoma: growth inhibition and differentiation of B16-F10.9 tumor cells. Oncogene 75: 569-577, 1997.
33. Hahne M, Rimoldi D, Shoroter M, et al: Melanoma cell expression of Fas (Apo-1/CD95) ligand: Implications for tumor immune escape. Science 274: 1363-1366, 1996.
34. Fearon DT: Seeking wisdom in innate immunity. Nature 388: 323-324, 1997.